International prognostic scoring system for Waldenström macroglobulinemia

Key Findings

• ●Developed IPSSWM with 5 adverse covariates: age >65, Hb <=11.5, platelets <=100K, B2M >3, IgM >7g/dL
• ●5-year survival: low risk 87%, intermediate 68%, high 36%
• ●Applicable across treatment regimens

Referenced in (1 disease)

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.